Filing summary
Registrant mismatch: The supplied filing is Chavant Capital Acquisition Corp.’s Form 10-K, not a filing for MOBIX LABS, INC. It covers the fiscal year ended December 31, 2021; the financial statements report activity from the company’s March 19, 2021 inception through year-end, not a standalone fourth quarter.
Business context
Chavant was a newly formed Cayman Islands SPAC with no operating business or revenue. It completed an $80 million IPO in July 2021 and was seeking an initial business combination. At year-end, it had not completed one. Its charter provided a 12-month period from the IPO closing to complete a combination, subject to the terms described in the filing.
Financial position and results
| Metric | Reported amount |
|---|---|
| Revenue | None; no operations had commenced |
| Operating expenses, inception to year-end | $762,456 |
| Net income, financial statements | $361,059, including a $1,120,738 noncash gain from the change in fair value of warrant liabilities and $2,777 of interest income |
| Operating cash flow | $(1,126,045) |
| Cash outside trust | $240,706 |
| Trust account | $80,002,777 |
| Working capital deficiency | $1,062,967 |
| Total liabilities | $1,736,264, including a $1,667,262 warrant liability |
| Long-term debt | None reported; no working capital loans were outstanding at year-end |
Public shares subject to possible redemption were presented as $80 million of temporary equity. The filing reports no operating margins because the company had no revenue. The statement of operations reports basic and diluted income per redeemable share of $0.38 and loss per nonredeemable share of $0.73.
Changes and unusual items
- The IPO and private placement generated gross proceeds of $83.4 million; $80 million was placed in trust. The company retained cash outside the trust for working capital.
- The financial statements cover the company’s first year from inception; no prior-year comparable operating period is presented.
- The MD&A says the company had a net loss of approximately $361,000, but the audited statement of operations reports net income of $361,059. The filing text is internally inconsistent on this point.
- Private placement warrants are accounted for as liabilities and remeasured through earnings, producing a material noncash gain in the period.
- A $2.8 million business-combination marketing fee was contingent on completing a business combination.
Outlook, liquidity, and risks
Management said available cash outside the trust was not expected to fund operations for the 12 months following issuance of the financial statements if no business combination occurred. The auditor highlighted substantial doubt about the company’s ability to continue as a going concern. Management planned to address liquidity through completing a business combination, but gave no assurance it would succeed or do so within the permitted period.
The company disclosed a material weakness in internal control over financial reporting related to earnings-per-share presentation and concluded that disclosure controls were ineffective at December 31, 2021. Management described remediation plans, but provided no assurance they would be effective. Other notable risks include redemption levels or financing needs preventing a transaction from closing, competition for targets, creditor claims against trust funds, and warrants potentially expiring worthless if no combination is completed. The filing reported no material litigation pending at year-end.
Investor verification checklist
- Confirm the intended issuer: the supplied filing is for Chavant Capital Acquisition Corp., not MOBIX LABS, INC.
- Reconcile the MD&A’s stated net loss with the audited statement’s reported net income and the related EPS calculations.
- Review the going-concern disclosure, cash available outside the trust, working capital deficiency, and any subsequent financing or business-combination developments.
- Check remediation progress for the disclosed earnings-per-share control weakness.
- Verify the business-combination deadline, redemption terms, contingent marketing fee, and potential dilution from warrants and any transaction financing.